Related Experiment Videos

Chlamydia pneumoniae and atherosclerosis following carotid endarterectomy

Babak S Jahromi1, Michael D Hill, Kate Holmes

  • 1Department of Neurosurgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|December 16, 2003
PubMed

Insights

This study found no evidence that Chlamydia pneumoniae infection causes carotid atherosclerosis progression, restenosis, or mortality in patients who underwent carotid endarterectomy. Further research is needed to clarify the role of this bacterium in cardiovascular disease.

Area of Science:

  • Cardiovascular Science
  • Infectious Disease Epidemiology
  • Pathology

Background:

  • Seroepidemiological studies suggest a link between Chlamydia pneumoniae antibodies and carotid atherosclerosis or stroke.
  • Direct evidence for a causal role of arterial C. pneumoniae infection in carotid disease is limited.
  • This study investigated the role of C. pneumoniae in carotid atherosclerosis through long-term follow-up of patients with proven arterial infection.

Purpose of the Study:

  • To determine if pathological evidence of Chlamydia pneumoniae infection in carotid plaques influences restenosis, contralateral progression, or mortality.
  • To investigate the potential causal role of C. pneumoniae in advanced carotid atherosclerosis.

Main Methods:

  • A cohort of 70 carotid endarterectomy patients were followed for a median of four years.
  • Chlamydia pneumoniae presence in carotid plaques was assessed using immunohistochemistry.
  • Survival analysis, including log-rank testing, compared outcomes between infected and non-infected groups.

Main Results:

  • No significant differences in all-cause mortality were observed between patients with and without C. pneumoniae in their carotid plaques.
  • Combined outcomes of mortality, restenosis, and progression also showed no difference between the groups.
  • Baseline demographic and cardiovascular risk factors were comparable between the study groups.

Conclusions:

  • The study found no causal role for Chlamydia pneumoniae in restenosis or progression of carotid disease.
  • No evidence suggests C. pneumoniae infection contributes to mortality in patients with advanced carotid atherosclerosis.
  • The findings do not support a link between arterial C. pneumoniae infection and adverse cardiovascular outcomes in this cohort.
Abstract

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...